All In Biotech

Free tool

FAERS Monitor: Krazati

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216340 or its brand name (Krazati, Adagrasib). Reports on generic versions are filed under their own applications.

Reports

1,134

Serious

878

77% of reports

Hospitalization

423

Death reported

349

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death306
  • diarrhoea133
  • hospitalisation116
  • nausea106
  • off label use95
  • vomiting90
  • asthenia72
  • fatigue63
  • decreased appetite48
  • dehydration43
  • dyspnoea40
  • acute kidney injury36
  • renal failure33
  • dizziness28
  • weight decreased26

Reports by year received

View as table
YearReports
20211
20226
2023365
2024385
2025201
2026176

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,025 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hospitalisationSignal11614.011.81,398
deathSignal3066.66.01,507
dehydrationSignal436.04.5174
renal failureSignal334.63.390
acute kidney injurySignal364.43.291
decreased appetiteSignal483.82.999
diarrhoeaSignal1333.83.3283
astheniaSignal723.62.8132
vomitingSignal903.62.9166
nauseaSignal1062.52.196
off label useSignal952.01.749
weight decreased261.71.27
fatigue631.51.210
dyspnoea401.31.03
dizziness281.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.